Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOHAN KESANI

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1578513362
CMS profile
297694
Location
MUNSTER, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,040.14

65 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,040.14 65

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOHAN KESANI

NPI 1578513362 · CMS profile ID 297694

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

MUNSTER, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578513362?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOHAN KESANI, NPI 1578513362, CMS profile ID 297694. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578513362?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MOHAN KESANI, NPI 1578513362, CMS profile ID 297694. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578513362?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MOHAN KESANI, NPI 1578513362, CMS profile ID 297694, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1578513362?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

65 matching records · $2,040.14 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 65 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–65 of 65.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $14.8803/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087007432 CMS
Novo Nordisk Inc $120.6503/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096686684 CMS
Nuwellis, Inc. $97.4703/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1088916579 CMS
E.R. Squibb & Sons, L.L.C. $7.0402/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101208280 CMS
Kestra Medical Technology Services, Inc. $20.9802/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152378003 CMS
Kiniksa Pharmaceuticals International, plc $16.8302/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154893806 CMS
Novartis Pharmaceuticals Corporation $14.5802/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087007436 CMS
E.R. Squibb & Sons, L.L.C. $15.0001/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101208278 CMS
Novartis Pharmaceuticals Corporation $15.6001/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087007428 CMS
Merck Sharp & Dohme LLC $16.7801/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141912041 CMS
SCPHARMACEUTICALS INC. $20.7401/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132244299 CMS
AstraZeneca Pharmaceuticals LP $35.5601/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104267039 CMS
Novartis Pharmaceuticals Corporation $19.6901/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087007434 CMS
Novartis Pharmaceuticals Corporation $17.3601/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087007426 CMS
Boston Scientific Corporation $125.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092512711 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,105.77 84
PY2020 $819.08 47
PY2021 $2,391.77 85
PY2022 $2,537.26 83
PY2023 $3,427.95 62
PY2024 $2,040.14 65
PY2025 $1,428.81 53

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,360.28 10
PY2025 Principal investigator $577,688.01 86
PY2024 Recipient $665.05 1
PY2024 Principal investigator $343,309.60 29
PY2023 Recipient $3,036.79 1
PY2023 Principal investigator $178,079.78 11
PY2022 Principal investigator $21,595.00 3
PY2021 Principal investigator $32,185.00 4
PY2019 Principal investigator $1,300.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

96 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $108.00 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651039
Principal investigator 1 Boehringer Ingelheim International GmbH $97.20 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651041
Principal investigator 1 Boehringer Ingelheim International GmbH $49.95 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651043
Principal investigator 1 Boehringer Ingelheim International GmbH $71.55 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651045
Principal investigator 1 Boehringer Ingelheim International GmbH $94.50 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651047
Principal investigator 1 Boehringer Ingelheim International GmbH $97.20 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651049
Principal investigator 1 Boehringer Ingelheim International GmbH $90.45 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651051
Principal investigator 1 Boehringer Ingelheim International GmbH $94.50 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651053
Principal investigator 1 Boehringer Ingelheim International GmbH $194.40 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651057
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651059
Principal investigator 1 Boehringer Ingelheim International GmbH $94.50 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651061
Principal investigator 1 Boehringer Ingelheim International GmbH $194.40 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651063
Principal investigator 1 Boehringer Ingelheim International GmbH $47.25 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651065
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651067
Principal investigator 1 Boehringer Ingelheim International GmbH $499.50 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651069
Principal investigator 1 Boehringer Ingelheim International GmbH $37.80 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651071
Principal investigator 1 Boehringer Ingelheim International GmbH $40.50 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651073
Principal investigator 1 Boehringer Ingelheim International GmbH $75.60 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651077
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651079
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 12/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651081
Principal investigator 1 Boehringer Ingelheim International GmbH $2,263.95 12/22/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651055
Principal investigator 1 Boehringer Ingelheim International GmbH $600.75 12/22/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651075
Principal investigator 1 Boehringer Ingelheim International GmbH $3,202.20 11/27/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651033
Principal investigator 1 Boehringer Ingelheim International GmbH $18,825.75 11/27/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651035
Principal investigator 1 Boehringer Ingelheim International GmbH $600.75 11/27/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651037
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 11/19/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651089
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 11/19/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220651111
Principal investigator 1 Boehringer Ingelheim International GmbH $302.64 11/19/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220651113
Principal investigator 1 Verona Pharma, Inc. $6,212.19 10/29/2025 Non-covered Recipient Entity
ASHA CLINICAL RESEARCH MUNSTER
Verona No dispute reported 06/30/2026 1232892813
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 10/27/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651083
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 10/27/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651085
Principal investigator 1 Boehringer Ingelheim International GmbH $151.32 10/27/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651087
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 10/27/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220651109
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 10/22/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651021
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 10/22/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651023
Principal investigator 1 Boehringer Ingelheim International GmbH $124.00 10/22/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651025
Principal investigator 1 Boehringer Ingelheim International GmbH $80.00 10/22/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651027
Principal investigator 1 Boehringer Ingelheim International GmbH $9.72 10/22/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651029
Principal investigator 1 Boehringer Ingelheim International GmbH $36.00 10/22/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651031
Principal investigator 1 Boehringer Ingelheim International GmbH $179.82 09/24/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220651101
Principal investigator 1 Boehringer Ingelheim International GmbH $547.50 09/24/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220651103
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 09/24/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220651105
Recipient GlaxoSmithKline, LLC. $161.64 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192143626
Recipient GlaxoSmithKline, LLC. $119.99 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192143630
Recipient GlaxoSmithKline, LLC. $237.63 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192143634
Recipient GlaxoSmithKline, LLC. $34.91 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192143638
Recipient GlaxoSmithKline, LLC. $113.85 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192143642
Recipient GlaxoSmithKline, LLC. $915.60 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192143645
Recipient GlaxoSmithKline, LLC. $103.36 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192144270
Recipient GlaxoSmithKline, LLC. $20.94 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192144275
Recipient GlaxoSmithKline, LLC. $37.40 09/10/2025 Covered Recipient Physician A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192144279
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 08/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651011
Principal investigator 1 Boehringer Ingelheim International GmbH $319.68 08/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651013
Principal investigator 1 Boehringer Ingelheim International GmbH $876.00 08/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651015
Principal investigator 1 Boehringer Ingelheim International GmbH $8.00 08/26/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651017
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 07/01/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220650997
Principal investigator 1 AstraZeneca Pharmaceuticals LP $984.11 06/23/2025 Non-covered Recipient Entity
ASHA CLINICAL RESEARCH - MUNSTER
A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non cirrhotic Non alcoholic Steatohepatitis with Fibrosis No dispute reported 06/30/2026 1185548683
Principal investigator 1 Janssen Research & Development, LLC $384.00 06/23/2025 Non-covered Recipient Entity
Asha Clinic Rsrch - Munster Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175246245
Principal investigator 1 Janssen Research & Development, LLC $4,226.00 06/20/2025 Non-covered Recipient Entity
Asha Clinic Rsrch - Munster Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175246329
Principal investigator 1 Janssen Research & Development, LLC $14,092.00 06/16/2025 Non-covered Recipient Entity
Asha Clinic Rsrch - Munster Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175246177
Principal investigator 1 Janssen Research & Development, LLC $5,280.00 06/16/2025 Non-covered Recipient Entity
Asha Clinic Rsrch - Munster Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175246183
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 06/01/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651009
Principal investigator 1 Eli Lilly and Company $265.85 05/28/2025 Non-covered Recipient Entity
ASHA CLINICAL RESEARCH-MUNSTER LLC
A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1187880865
Principal investigator 1 Verona Pharma, Inc. $3,906.79 05/02/2025 Non-covered Recipient Entity
ASHA CLINICAL RESEARCH MUNSTER
Verona No dispute reported 06/30/2026 1232892711
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 05/01/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220650995
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 04/01/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220650991
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 03/25/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220650981
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 03/25/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220650983
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 03/25/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220650985
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 03/25/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220650987
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 03/25/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220650989
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 03/25/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220651091
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 03/25/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220651093
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 03/25/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220651095
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 03/25/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220651097
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 03/25/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220651099
Principal investigator 1 Boehringer Ingelheim International GmbH $66,960.00 03/12/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651019
Principal investigator 1 Boehringer Ingelheim International GmbH $66,960.00 03/12/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220651107
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 03/01/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220650993
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 02/28/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220650965
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 02/28/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220650967
Principal investigator 1 Boehringer Ingelheim International GmbH $239.89 02/28/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220650969
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 02/28/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220650971
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/28/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220650973
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/28/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220650975
Principal investigator 1 Boehringer Ingelheim International GmbH $21.43 02/28/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220650977
Principal investigator 1 Boehringer Ingelheim International GmbH $33.71 02/28/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220650979
Principal investigator 1 Verona Pharma, Inc. $10,500.00 02/14/2025 Non-covered Recipient Entity
ASHA CLINICAL RESEARCH MUNSTER
Verona No dispute reported 06/30/2026 1232892681
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 02/01/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220650999
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651001
Principal investigator 1 Boehringer Ingelheim International GmbH $75.00 02/01/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651003
Principal investigator 1 Boehringer Ingelheim International GmbH $75.00 02/01/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651005
Principal investigator 1 Boehringer Ingelheim International GmbH $28.00 02/01/2025 Non-covered Recipient Entity
Cardiovascular Consultants PC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220651007
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,671.70 01/31/2025 Non-covered Recipient Entity
ASHA CLINICAL RESEARCH - MUNSTER
A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function No dispute reported 06/30/2026 1185548685
Principal investigator 1 Eli Lilly and Company $343,191.00 01/07/2025 Non-covered Recipient Entity
ASHA CLINICAL RESEARCH-MUNSTER LLC
A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1187877757
Recipient Eli Lilly and Company $614.96 01/02/2025 Covered Recipient Physician A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1187871753